Delivery Order SPE2DB20D3505-SPE2DB25FU5M0
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3 ml vials, with a contract ceiling value of $43,208.69. This firm fixed-price delivery order, with an ultimate completion date of July 25, 2025, represents a routine pharmaceutical procurement under a competitively awarded, non-set-aside contract vehicle. The work will be performed at AmerisourceBergen's corporate office location...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3 mL vials, with a contract ceiling value of $31,796.89. This is a firm fixed-price delivery order with an ultimate completion date of August 28, 2025, and represents a non-set-aside, competitively awarded procurement. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Ozempic (semaglutide) 0.25–0.5 mg/dose pens in 3 mL formulations. This competitively awarded, non-set-aside delivery order carries a ceiling value of $32,930.62 under firm fixed-price terms, with an ultimate completion date of August 19, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3 ml vials, with a ceiling value of $2,819.97. This is a firm fixed-price delivery order with an ultimate completion date of August 5, 2025, and no set-aside designation was applied. The order will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3 mL formulations, valued at $8,976.61. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 10, 2025, with performance at the vendor's facility in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting open competition among qualified pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $4,893.47 to AmerisourceBergen Drug Corp for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3 ml vials. This non-competitive, firm fixed-price delivery order was awarded on September 15, 2025, with an ultimate completion date of September 16, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The order represents a routine pharmaceutical procurement within the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3 ml quantities, with a ceiling value of $8,934.28. This is a firm fixed-price delivery order executed under a competitive process with no set-aside designation. The contract is set to be completed by August 20, 2025, and represents fulfillment under AmerisourceBergen's broader pharmaceutical supply agreements with the Defense...
- The Defense Logistics Agency awarded a delivery order valued at $1,879.98 to AmerisourceBergen Drug Corp for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3ml vials. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, with an ultimate completion date of September 26, 2025. The award was issued on September 25, 2025, and the pharmaceutical will be delivered to AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Ozempic (0.25-0.5 mg/dose pen, 3ml formulation) with a ceiling value of $19,962.14. This firm fixed-price delivery order, which is non-set-aside and competitively awarded, is scheduled for completion by August 1, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a typical pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens in 3ml vials, with a ceiling value of $16,813.02. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of September 26, 2025. The order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company maintains its...
- SPE2DB20D3505Indefinite Delivery Contract
- SPE2DB20D3505-SPE2DB25FU5M0Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 6, 2025, for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3ml vials, with a ceiling value of $7,944.85. This is a firm fixed-price delivery order with no set-aside designation, completed competitively through open procurement. The order is scheduled for ultimate completion on May 7, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This comprehensive pharmaceutical vehicle enables AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare systems globally. The company serves as a critical federal vendor through the Defense Health Agency and other government healthcare systems, with its federal contract portfolio demonstrating consistent capability in delivering both brand-name and generic pharmaceuticals across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.9k | 5/6/25 |